Inhibrx

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to the company and press accounts, the trial met its primary endpoint with a statistically significant jump in progression-free survival (PFS) biospace.com. Patients on ozekibart lived a median 5.52 months without progression versus 2.66 months on placebo – a 52% reduction in the risk of progression or death biospace.com. All patient subgroups (including those with or without IDH mutations) saw benefit,